FDA Accepts Application to Review Dapagliflozin, a Type 2 Treatment

The U.S. Food and Drug Administration has accepted an application to review dapagliflozin, a drug for the treatment of type 2 diabetes that is being developed by Bristol-Myers Squibb and AstraZeneca.

Dapagliflozin differs from conventional type 2 drug treatments that target insulin production or use. Instead, dapagliflozin targets sodium-glucose cotransporter-2 (SGLT2), which is located in the kidney. By doing so, the drug encourages the excretion of excess glucose and calories. (Its mechanism of action is described in the recent Diabetes Health article, “Flushing Away High Blood Sugar.”)

FDA approval could come by late October this year. The manufacturers have also applied for European approval with the European Medicines Agency.

Before applying to U.S. and European regulators, Bristol-Meyers and AstraZeneca studied dapagliflozin’s effects on 6,000 subjects enrolled in 40 clinical studies. For the U.S. market, they also tracked any correlation between the use of the drug and potential cardiovascular problems.

Comments

comments

Join our e-newsletter!

Complete the form below to subscribe to our email newsletter.

First Name

Last Name

Email *

Email Consent * I give Celebrity Sites LLC permission to send me email about new products, services and special offers.

Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.